ATP7B and Wilson disease: Although in these instances both targets and mechanisms of action of the peptide have yet to be determined, these results strongly support the outcome of our main finding: to deploy the Pept 73–92 for developing new effective drugs to contrast the form of Wilson disease caused by the ATP7B-H1069Q mutation, which is harbored in more than 50% of the Caucasian patients [6], firstly because the peptide shows clearly good access inside the cell, either in tissue culture or in vivo.